-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $35 at Leerink Partners
-
-
-
-
-
-
-
Intellia presents longer-term data for hereditary angioedema treatment
-
-
-
-
-
-
-
William Blair Upgrades Intellia Therapeutics (NTLA) to Outperform
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
-
-
-
-
-
-
-
Baird Reiterates Neutral Rating on Intellia Therapeutics (NTLA)
-
-
-
-
-
-
-
FDA places clinical hold on Intellia's MAGNITUDE trials for nex-z
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Lowered to $33 at Oppenheimer
-
408,898 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

